InvestorsHub Logo
Followers 60
Posts 7390
Boards Moderated 0
Alias Born 10/20/2014

Re: momoney24 post# 313159

Thursday, 12/03/2020 8:12:20 PM

Thursday, December 03, 2020 8:12:20 PM

Post# of 425850
Understood, But I am suggesting a comprehensive strategy that would use
attorneys to go after any purveyor of a product that is sold in lieu of
branded Vascepa. The strategy would be to educate doctors and patients
on the dangers of any substitute for branded Vascepa...that would include
generic Vascepa, generic Lovaza, OTC fish oil, or any product that takes
away CV patients from branded Vascepa. This would be done through DTC
commercials as well as referrals to attorneys who will fight for CVD
patients harmed by any product used to deny that patients Vascepa.

The amazingly effective product that AMRN has is never going to be
accepted until BP owns the company. My suggested strategy is a
stop-gap measure until BP steps in. Sadly, nobody knows what
an Amarin is or what exactly Vascepa is and does. This situation
is costing people needless bad events and in some cases even their
very lives. JT of all people should understand that Vascepa in the
right hands will do very well. JT's job should be to insure Vascepa
is sold to the right BP to BOTH maximize shareholder value as well
as to insure the optimal uptake of Vascepa around the world.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News